MARKET

RZLT

RZLT

Rezolute Inc
NASDAQ
2.690
+0.040
+1.51%
Closed 16:00 02/03 EST
OPEN
2.670
PREV CLOSE
2.650
HIGH
2.770
LOW
2.650
VOLUME
14.84K
TURNOVER
30.29K
52 WEEK HIGH
5.01
52 WEEK LOW
1.340
MARKET CAP
99.07M
P/E (TTM)
-1.3813
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 12/16/2022 13:07
Rezolute Initiates Phase 2 Study of Treatment for Diabetic Macular Edema
Rezolute Initiates Phase 2 Study of Treatment for Diabetic Macular Edema
MT Newswires · 12/15/2022 10:08
Rezolute GAAP EPS of -$0.19
Seekingalpha · 11/09/2022 22:27
Rezolute Q1 EPS $(0.19) Up From $(0.92) YoY
Benzinga · 11/09/2022 21:51
-- Earnings Flash (RZLT) REZOLUTE Reports Q1 Loss $-0.19
-- Earnings Flash (RZLT) REZOLUTE Reports Q1 Loss $-0.19
MT Newswires · 11/09/2022 16:17
BRIEF-Rezolute Inc Files Prospectus Relates To Resale Of 3.2 Million Shares Of Common Stock By Selling Stockholders
Reuters · 10/28/2022 20:30
Rezolute Files Prospectus Relates To Resale Of 3.2M Shares Of Common Stock By Selling Stockholders
Benzinga · 10/28/2022 20:09
Rezolute Unveils Plans for Secondary Offering of 3.24 Million Shares
Rezolute Unveils Plans for Secondary Offering of 3.24 Million Shares
MT Newswires · 10/28/2022 16:47
More
About RZLT
Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.

Webull offers kinds of Rezolute Inc stock information, including NASDAQ:RZLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RZLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RZLT stock methods without spending real money on the virtual paper trading platform.